Anastasia Voznesenskaya

Dr. Anastasia Voznesenskaya

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
AVAnastasia Voznesenskaya
Anastasia Voznesenskaya
ASAlena Sorokina
Alena Sorokina
MSMarina Shestakova
Marina Shestakova
ESEkaterina Shestakova
Ekaterina Shestakova
IMIldar R. Minniakhmetov
Ildar R. Minniakhmetov
MLMarina Yu Loguinova
Marina Yu Loguinova
Of the many clinical phenotypes of obesity, the most prevalent are metabolically “healthy” (MHO) and metabolically “unhealthy” (MUO) obesities, the latter being associated with a range of comorbidities, including type 2 diabetes mellitus (T2DM). The underlying causes of different obesity phenotypes and the mechanisms of conversion of one phenotype into another have yet to be fully elucidated. However, increasing evidence suggests the key role of low-grade metabolic inflammation (metaflammation) in the pathogenesis of obesity and metabolic dysfunction. The review presents a comprehensive description of changes in immune cell populations and pro-inflammatory mediators, as well as a detailed comparative mapping of the adipose tissue immune landscape during MHO/MUO transition. Based upon a conceptual model for the intensification of metaflammation during MHO progression and conversion to MUO, a pattern of dynamical changes that accompany MHO/MUO transition is described. Though many parameters demonstrate significant differences in multiple cross-sectional and some longitudinal studies, only a few of them (CRP, IL-6, IL-17A, absolute counts of leukocytes and neutrophils) meet the criteria of a validated biomarker in clinical setting. A lack of standardization in MHO definition and heterogeneity in the severity of MUO make the search for predictive biomarkers a challenge. The review also discusses the mechanisms underlying metabolic memory and the incomplete reversibility of metabolic disturbances after bariatric surgery.

18 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
AVAnastasia Voznesenskaya
Anastasia Voznesenskaya
ASAlena Sorokina
Alena Sorokina
MSMarina Shestakova
Marina Shestakova
ESEkaterina Shestakova
Ekaterina Shestakova
IMIldar R. Minniakhmetov
Ildar R. Minniakhmetov
MLMarina Yu Loguinova
Marina Yu Loguinova
Of the many clinical phenotypes of obesity the most prevalent are metabolically “healthy” (MHO) and metabolically “unhealthy” obesity (MUO), the latter being associated with a range of comorbidities, in-cluding type 2 diabetes mellitus (T2DM). The underlying causes of different obesity phenotypes and the mechanisms of conversion of one phenotype into another, have yet to be fully elucidated. However, in-creasing evidence suggests the key role of low-grade metabolic inflammation (metaflammation) in patho-genesis of obesity and metabolic dysfunction. This review compares numerous pro-inflammatory media-tors observed in MHO and MUO to identify the role of metaflammation in obesity phenotype. A mechanis-tic model is proposed for the progression from MHO to MUO with the exacerbation of metaflammation and dysfunction of insulin-sensitive organs. MUO is characterized by the excess of visceral adiposity, both local and systemic insulin resistance (IR). Obesity is accompanied by a shift in the immune profile from anti-inflammatory to pro-inflammatory, with its worsening in MUO. However no clinically significant pa-rameter has been identified among soluble factors or leukocyte subtypes in the blood as a predictor of MHO to MUO conversion. Structural and functional changes in adipose tissue are not resolved immediately following bariatric interventions. The persistence of «metabolic memory» in the form of epigenetic modi-fications in macrophages of adipose tissue and the emergence of large numbers of CD4+ and CD8+ effec-tor memory T cells with senescent phenotype, may predispose to weight regain and T2DM relapse post-surgery. The review discusses mechanisms underlying metabolic memory and potential reversibility of metabolic disturbances after bariatric surgery.

14 July 2023 in Clinical and experimental thyroidology
Verified
Journal Article
Open access
PDF file
EKE. A. Kolpakova
E. A. Kolpakova
AVAnastasia Voznesenskaya
Anastasia Voznesenskaya
NFN. V. Frolkova
N. V. Frolkova
ETEkaterina Troshina
Ekaterina Troshina
Levothyroxine steadily maintains its position as the «gold standard» in the treatment of hypothyroidism. Despite the possibility of step-by-step tableted dose titration of levothyroxine, the results of many studies reliably point to the fact that a significant number of patients do not reach the target level of thyroid hormone. One of the main reasons for the therapy ineffectiveness is the inconvenience of levothyroxine sodium regimen for many patients, associated with the need to observe certain time intervals before meals and other medications. The above-mentioned factors have stimulated a number of studies aimed at developing new dosage forms with significant advantages in the pharmacokinetics and pharmacodynamics of drugs. The review provides the latest data on the new dosage forms of levothyroxine. Further large-scale clinical trials are needed for a more reasonable and widespread use of new dosage forms of levothyroxine in clinical practice.

15 September 2024 in Problems of Endocrinology
Verified
Journal Article
Open access
PDF file
LDLarisa K Dzeranova
Larisa K Dzeranova
EPEKATERINA PIGAROVA
EKATERINA PIGAROVA
SVS. Yu. Vorotnikova
S. Yu. Vorotnikova
AVAnastasia Voznesenskaya
Anastasia Voznesenskaya
Autoimmune/lymphocytic hypophysitis is one of the rare causes of central diabetes insipidus in adults and is most common among women in the second or third trimester of pregnancy. Numerous studies have shown that lymphocytic hypophysitis is characterized by a very variable clinical signs with the development of neurological symptoms, visual disturbances and hypopituitarism with partial or complete loss of pituitary function, as well as a number of features in magnetic resonance imaging (MRI). Isolated lymphocytic indibuloneurohypophysitis occurs in fewer cases and involves the posterior lobe and stalk of the pituitary gland with a clinical presentation of diabetes insipidus. The above clinical case describes the development of hypophysitis in a pregnant woman with a predominant lesion of the posterior pituitary gland and an outcome in diabetes insipidus, which persists 6 years after pregnancy and childbirth. In the article some aspects of the differential diagnosis of diabetes insipidus in pregnant women, as well as instrumental diagnosis and treatment approaches of hypophysitis are discussed.

9 October 2025 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
ESEkaterina Shestakova
Ekaterina Shestakova
ATA. O. Tomilova
A. O. Tomilova
MSM. D. Samsonova
M. D. Samsonova
AVAnastasia Voznesenskaya
Anastasia Voznesenskaya
MSM. S. Sineokaya
M. S. Sineokaya
MSMarina Shestakova
Marina Shestakova
BACKGROUND : The effect of glucagon on metabolic processes is ambiguous: on the one hand, an excess of this hormone in the postprandial period increases glycemia, on the other hand, it can contribute to weight loss. In this regard, it is important to assess the secretion of the natural glucagon/glucagon-like peptide-1 coagonist oxyntomodulin in obese individuals with or without type 2 diabetes (T2D). AIM : To investigate the secretion levels of GLP-1, glucagon, and the GLP-1/glucagon coagonist oxyntomodulin in patients with obesity, with or without T2D, during the weight loss process after bariatric surgery. MATERIALS AND METHODS : The study involved participants with morbid obesity, with or without T2D, all of whom underwent bariatric surgery. Prior to the procedure, and then at 3 and 6 months post-surgery, the patients participated in hyperinsulinemic euglycemic clamp tests and OGTT. During these assessments, glucose, glucagon, GLP-1, and oxyntomodulin levels were measured at 0, 30, and 120 minutes. RESULTS : The research included 44 obese patients without T2D and 42 with T2D. Baseline characteristics, including age, height, weight, BMI, waist circumference, and hip circumference, did not show significant differences between the two groups. Patients without T2D showed a lower degree of insulin resistance, a lower glucagon level, and greater preservation of GLP-1 secretion. Additionally, these patients initially exhibited higher levels of oxyntomodulin compared to those with T2D (area under the curve 2.08 [1.61; 2.50] ng/ml*h vs 1.64 [1.07; 1.78] ng/ml*h , p<0.00005). Following weight loss, oxyntomodulin secretion levels rose in both groups (in the T2DM (-) group: 2.35 [1.9; 3.28] ng/ml*h at 3 months, 2.55 [2.02; 3.35] ng/ml*h at 6 months, p<0.00001; in the T2DM (+) group: 2.27 [1.95; 2.61] ng/ml*h at 3 months; 2.4 [1.99; 2.72] ng/ml*h at 6 months, p<0.00001) with no significant intergroup differences at 3 and 6 months after ­surgery. CONCLUSION : Baseline oxyntomodulin levels were significantly higher in patients with normal carbohydrate metabolism than in patients with type 2 diabetes and increased equally in both groups at 3 and 6 months after bariatric intervention. These results may indicate potential protective functions of oxyntomodulin, but further studies are needed.

23 May 2023 in Obesity and metabolism
Verified
Journal Article
Open access
PDF file
NMN. V. Molashenko
N. V. Molashenko
NKNatalia Kalinchenko
Natalia Kalinchenko
VIVitaliy Ioutsi
Vitaliy Ioutsi
OGO. S. Gurinovich
O. S. Gurinovich
DBD. M. Babaeva
D. M. Babaeva
МЮМ. Ю. Юкина
М. Ю. Юкина
17β-Hydroxysteroid dehydrogenase 3 deficiency (17HSD3) is a rare autosomal recessive cause of 46, XY disorders of sex development resulting from HSD17B3 gene mutations, in which conversion of androstenedione to testosterone is impared. The clinical signs of 17HSD3 deficiency depend on the residual activity of the enzyme. The diagnosis of 17HSD3 deficiency is based on reduced testosterone/androstenedione ratio (T/AD < 0.8). Patients are usually assigned at birth and raise as female. If the diagnosis is made before puberty, gonadectomy is recommended, taking into account the risk of masculinization during the puberty and estrogen therapy initiation in this period. If the diagnosis of 17HSD3 deficiency is established during puberty, when virilization manifests, the therapeutic strategy is based on the results of comprehensive psychological testing and gender identity of a patient. In patients with more pronounced masculinization or diagnosis established shortly after birth, who are assigned at birth and raise as male, testosterone therapy is used to achieve a male phenotype. The 17HSD3 deficiency and virilization often result in a change of gender identity during puberty. The article presents a clinical case of 17-βhydroxysteroid dehydrogenase type 3 deficiency with late diagnosis due to parental will. The diagnostic approaches and management of the disease are also described.